PMID- 31735010
OWN - NLM
STAT- MEDLINE
DCOM- 20200330
LR  - 20200330
IS  - 1087-2108 (Electronic)
IS  - 1087-2108 (Linking)
VI  - 25
IP  - 10
DP  - 2019 Oct 15
TI  - Widespread subacute cutaneous lupus erythematosus in a patient receiving 
      checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.
LID - 13030/qt4md713j8 [pii]
AB  - Checkpoint inhibitor immunotherapy, including ipilimumab and nivolumab, is 
      associated with numerous immune-related adverse events including dermatitis, 
      pruritus, hepatitis, diarrhea, and hypophysitis. As the number of patients 
      undergoing immunotherapy treatment increases, however, rare and unusual 
      immune-related adverse events are observed. Many of these resemble known 
      autoimmune phenomenon, such as subacute lupus erythematosus and myositis. Herein, 
      we report a patient with metastatic serous ovarian carcinoma undergoing treatment 
      with combination ipilimumab and nivolumab who developed subacute cutaneous lupus 
      erythematosus (SCLE). Recent case reports have documented SCLE as a novel 
      immune-related adverse event. In our case, she was able to successfully restart 
      immunotherapy after a course of oral corticosteroids and maintenance oral 
      hydroxychloroquine and topical corticosteroid therapy.
FAU - Kosche, Cory
AU  - Kosche C
FAU - Owen, Joshua L
AU  - Owen JL
FAU - Choi, Jennifer N
AU  - Choi JN
AD  - Department of Dermatology, Northwestern University, Feinberg School of Medicine, 
      Chicago, IL Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 
      Feinberg School of Medicine, Chicago, IL. Jennifer.Choi@northwestern.edu.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20191015
PL  - United States
TA  - Dermatol Online J
JT  - Dermatology online journal
JID - 9610776
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Ipilimumab)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents, Immunological/*adverse effects
MH  - Cell Cycle Checkpoints
MH  - Female
MH  - Humans
MH  - Immunotherapy/*adverse effects
MH  - Ipilimumab/*adverse effects
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/pathology
MH  - Nivolumab/*adverse effects
MH  - Ovarian Neoplasms/drug therapy
MH  - Skin/*pathology
EDAT- 2019/11/19 06:00
MHDA- 2020/03/31 06:00
CRDT- 2019/11/19 06:00
PHST- 2019/11/08 00:00 [received]
PHST- 2019/11/08 00:00 [accepted]
PHST- 2019/11/19 06:00 [entrez]
PHST- 2019/11/19 06:00 [pubmed]
PHST- 2020/03/31 06:00 [medline]
AID - 13030/qt4md713j8 [pii]
PST - epublish
SO  - Dermatol Online J. 2019 Oct 15;25(10):13030/qt4md713j8.